GSK's New Drug Launches Will be Key to 2027 Outlook

Dow Jones08-04

1438 GMT - GSK's newly launched drugs will be key to reduce risk on the U.K. pharmaceutical company's outlook for next year, analysts at J.P. Morgan say. GSK recently launched blood-cancer drug Blenrep and asthma treatment Exdensur, while lung-cancer medicine Jideytro--which the company bought through its acquisition of Nuvalent--received U.S. approval last month. The trajectory of these products and others that are expected to reach the market next year like hepatitis B drug bepirovirsen and neladalkib--another lung-cancer drug from Nuvalent--will be increasingly focus for investors, the analysts say. The company's efforts to accelerate its strategy look encouraging but, with the next pivotal study results due to come only in 2028, potential risks to earnings in the near term might draw investors' attention, they add. Shares rise 0.2%.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment